Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adefovir Expanded Access Enrollment Cited By Gilead To Support Approval

Executive Summary

Gilead's adefovir dipivoxil is currently being used by physicians responsible for 70% of the prescriptions for AIDS antiretroviral therapies in the U.S., via the company's expanded access program.

You may also be interested in...

An "Evolving" Standard for AIDS Drugs?

Antiviral Drugs Advisory Committee member John Hamilton, MD, suggested that advances in AIDS therapy have changed the equation for evaluating new agents. Here are his comments, as transcribed by "The Pink Sheet."

Gilead Adefovir Approval Awaits "Unequivocal" Evidence Of Efficacy At 60 mg

Gilead has begun enrollment in two placebo-controlled trials of a 60 mg dose of adefovir dipivoxil that could provide sufficient evidence to prompt a reconsideration of the HIV therapy by FDA's Antiviral Drugs Advisory Committee.

Bristol-Myers Squibb Videx

Once-daily oral dose of two 200 mg didanosine chewable tablets approved by FDA Oct. 28. Videx' revised label also includes risk information about pancreatitis in patients receiving triple combination therapy including Videx, Bristol's Zerit (stavudine) and a protease inhibitor. Labeling has also added a precaution that "pancreatitis resulting in death was observed in one patient who received Videx plus stavudine plus nelfinavir [Warner-Lambert's Viracept]...and in one patient who received Videx plus stavudine plus indinavir [Merck's Crixivan]." Two of 68 patients receiving Videx/Zerit/Crixivan and Bristol's Droxil (hydroxyurea) died from pancreatitis, labeling continues

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts